Cargando…

Assessing THK523 selectivity for tau deposits in Alzheimer’s disease and non–Alzheimer’s disease tauopathies

INTRODUCTION: The introduction of tau imaging agents such as (18)F-THK523 offers new hope for the in vivo assessment of tau deposition in tauopathies such as Alzheimer’s disease (AD), where preliminary (18)F-THK523-PET studies have demonstrated significantly higher cortical retention of (18)F-THK523...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fodero-Tavoletti, Michelle T, Furumoto, Shozo, Taylor, Leanne, McLean, Catriona A, Mulligan, Rachel S, Birchall, Ian, Harada, Ryuichi, Masters, Colin L, Yanai, Kazuhiko, Kudo, Yukitsuka, Rowe, Christopher C, Okamura, Nobuyuki, Villemagne, Victor L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3979096/ https://www.ncbi.nlm.nih.gov/pubmed/24572336 http://dx.doi.org/10.1186/alzrt240

Ejemplares similares

Longitudinal Assessment of Tau Pathology in Patients with Alzheimer’s Disease Using [(18)F]THK-5117 Positron Emission Tomography
por: Ishiki, Aiko, et al.
Publicado: (2015)

(18)F-THK5351 Positron Emission Tomography Imaging in Neurodegenerative Tauopathies
por: Ezura, Michinori, et al.
Publicado: (2021)

Dynamic PET Measures of Tau Accumulation in Cognitively Normal Older Adults and Alzheimer’s Disease Patients Measured Using [18F] THK-5351
por: Lockhart, Samuel N., et al.
Publicado: (2016)

Imaging of Reactive Astrogliosis by Positron Emission Tomography
por: Harada, Ryuichi, et al.
Publicado: (2022)

Neuroimaging-pathological correlations of [(18)F]THK5351 PET in progressive supranuclear palsy
por: Ishiki, Aiko, et al.
Publicado: (2018)

Characteristics of Tau and Its Ligands in PET Imaging
por: Harada, Ryuichi, et al.
Publicado: (2016)

Evaluation of (18)F labeled glial fibrillary acidic protein binding nanobody and its brain shuttle peptide fusion proteins using a neuroinflammation rat model
por: Morito, Takahiro, et al.
Publicado: (2023)

β-amyloid in biological samples: not all Aβ detection methods are created equal
por: Adlard, Paul A., et al.
Publicado: (2014)

Comparative binding properties of the tau PET tracers THK5117, THK5351, PBB3, and T807 in postmortem Alzheimer brains
por: Lemoine, Laetitia, et al.
Publicado: (2017)

Optimization and Biodistribution of [(11)C]-TKF, An Analog of Tau Protein Imaging Agent [(18)F]-THK523
por: Kong, Yanyan, et al.
Publicado: (2016)

Regional tau deposition and subregion atrophy of medial temporal structures in early Alzheimer's disease: A combined positron emission tomography/magnetic resonance imaging study
por: Sone, Daichi, et al.
Publicado: (2017)

Association of deposition of tau and amyloid‐β proteins with structural connectivity changes in cognitively normal older adults and Alzheimer’s disease spectrum patients
por: Shigemoto, Yoko, et al.
Publicado: (2018)

Imaging Protein Misfolding in the Brain Using β-Sheet Ligands
por: Harada, Ryuichi, et al.
Publicado: (2018)

Corrigendum: Imaging Protein Misfolding in the Brain Using β-Sheet Ligands
por: Harada, Ryuichi, et al.
Publicado: (2018)

Visualization of regional tau deposits using (3)H-THK5117 in Alzheimer brain tissue
por: Lemoine, Laetitia, et al.
Publicado: (2015)

Dissociation of Tau Deposits and Brain Atrophy in Early Alzheimer’s Disease: A Combined Positron Emission Tomography/Magnetic Resonance Imaging Study
por: Shigemoto, Yoko, et al.
Publicado: (2018)

Involvement of the Precuneus/Posterior Cingulate Cortex Is Significant for the Development of Alzheimer’s Disease: A PET (THK5351, PiB) and Resting fMRI Study
por: Yokoi, Takamasa, et al.
Publicado: (2018)

Evaluation of the biodistribution and radiation dosimetry of the (18)F-labelled amyloid imaging probe [(18)F]FACT in humans
por: Shidahara, Miho, et al.
Publicado: (2013)

Regional cerebral THK5351 accumulations correlate with neuropsychological test scores in Alzheimer continuum
por: Im, SungWoon, et al.
Publicado: (2023)

Untangling the Tauopathy for Alzheimer’s disease and parkinsonism
por: Chang, Hui-Yun, et al.
Publicado: (2018)

Synthesis and pharmacokinetic characterisation of a fluorine-18 labelled brain shuttle peptide fusion dimeric affibody
por: Morito, Takahiro, et al.
Publicado: (2021)

Imaging in-vivo tau pathology in Alzheimer’s disease with THK5317 PET in a multimodal paradigm
por: Chiotis, Konstantinos, et al.
Publicado: (2016)

Use of local genetic ancestry to assess TOMM40-523′ and risk for Alzheimer disease
por: Bussies, Parker L., et al.
Publicado: (2020)

Phosphorylated Tau in Alzheimer’s Disease and Other Tauopathies
por: Rawat, Priyanka, et al.
Publicado: (2022)

[(18)F]THK5317 imaging as a tool for predicting prospective cognitive decline in Alzheimer’s disease
por: Chiotis, Konstantinos, et al.
Publicado: (2020)

[(18)F]THK-5351 PET Patterns in Patients With Alzheimer’s Disease and Negative Amyloid PET Findings
por: Oh, Minyoung, et al.
Publicado: (2022)

Comparison of amyloid PET measured in Centiloid units with neuropathological findings in Alzheimer’s disease
por: Amadoru, Sanka, et al.
Publicado: (2020)

[(18)F]THK5351 PET Imaging in Patients with Mild Cognitive Impairment
por: Jeong, Hye Jin, et al.
Publicado: (2020)

PET Imaging of Tau Pathology in Alzheimer’s Disease and Tauopathies
por: James, Olga G., et al.
Publicado: (2015)

Prospects for strain-specific immunotherapy in Alzheimer’s disease and tauopathies
por: Bittar, Alice, et al.
Publicado: (2018)

Tau and neuroinflammation: What impact for Alzheimer's Disease and Tauopathies?
por: Laurent, Cyril, et al.
Publicado: (2018)

Effects of Deferasirox in Alzheimer’s Disease and Tauopathy Animal Models
por: Kwan, Ping, et al.
Publicado: (2022)

Type-I Interferons in Alzheimer's Disease and Other Tauopathies
por: Sanford, Sophie A. I., et al.
Publicado: (2022)

DNA Methylation in Genetic and Sporadic Forms of Neurodegeneration: Lessons from Alzheimer’s, Related Tauopathies and Genetic Tauopathies
por: Zimmer-Bensch, Geraldine, et al.
Publicado: (2021)

Dual tracer tau PET imaging reveals different molecular targets for (11)C-THK5351 and (11)C-PBB3 in the Alzheimer brain
por: Chiotis, Konstantinos, et al.
Publicado: (2018)

Combination of automated brain volumetry on MRI and quantitative tau deposition on THK-5351 PET to support diagnosis of Alzheimer’s disease
por: Kim, Minjae, et al.
Publicado: (2021)

Deep learning‐based model for diagnosing Alzheimer's disease and tauopathies
por: Koga, Shunsuke, et al.
Publicado: (2021)

APOE ε4-TOMM40 ‘523 haplotypes and the risk of Alzheimer’s disease in older Caucasian and African Americans
por: Yu, Lei, et al.
Publicado: (2017)

(18)F–THK–5351, Fluorodeoxyglucose, and Florbetaben PET Images in Atypical Alzheimer’s Disease: A Pictorial Insight into Disease Pathophysiology
por: Park, Sohee, et al.
Publicado: (2021)

The development and validation of tau PET tracers: current status and future directions
por: Okamura, Nobuyuki, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_qh370aos99nk3dmu8t9qsvcg0k